A Placebo-Controlled, Randomized Phase 2 Study of Conatumumab (C) or AMG 479 (A) or Placebo (P) + Gemcitabine (G) in Patients (pts) With Metastatic Pancreatic.

Slides:



Advertisements
Similar presentations
FOLFOXIRI plus bevacizumab (bev) vs FOLFIRI plus bev
Advertisements

Goede V et al. Proc ASCO 2013;Abstract 7004.
1 N9841: A Randomized Phase III Equivalence Trial of Irinotecan (CPT-11) versus FOLFOX4 in Patients with Advanced Colorectal Carcinoma Previously Treated.
Herceptin® (trastuzumab) in combination with chemotherapy: pivotal metastatic breast cancer survival data 1.
Introduction  Soft Tissue Sarcoma (STS) are a group of highly chemotherapy resistant tumors  Doxorubicin is the only APPROVED 1 st line chemotherapy.
Efficacy and Safety of Conatumumab Plus AMG 479 in Patients With Advanced Sarcoma S Chawla,1 AC Lockhart,2 N Azad,3 E Elez,4 F Galimi,5 N Baker,6 YJ.
An Academic Research Organization of Brigham and Women’s Hospital and Harvard Medical School LAPLACE-TIMI 57 Primary Results A Double-blind, Randomized,
Phase III Study Comparing Gemcitabine plus Cetuximab versus Gemcitabine in Patients with Locally Advanced or Metastatic Pancreatic Adenocarcinoma Southwest.
First-Line TKI Use in EGFR Mutation-Positive NSCLC
Phase III study of first-line XELOX plus bevacizumab (BEV) for 6 cycles followed by XELOX plus BEV or single agent (s/a) BEV as maintenance therapy in.
ASCO 2009 Safety and Efficacy of AMG 655 Plus Modified FOLFOX6 (mFOLFOX6) and Bevacizumab (B) for the First-line Treatment of Patients (Pts) With Metastatic.
SARC015: Phase II study of R1507 in wild-type GIST Margaret von Mehren, Fox Chase Cancer Center Katie Janeway, Dana Farber Cancer Institute.
Cabozantinib (XL184) in Metastatic Castration-Resistant Prostate Cancer (mCRPC): Results from a Phase II Randomized Discontinuation Trial Hussain M et.
Copyright © 2011 Research To Practice. All rights reserved. Case presented by Dr Schwartz 44 yo woman with 4 mo hx of abdominal pain –Imaging = pancreatic.
1 SNDA Gemzar plus Carboplatin Treatment of Late Relapsing Ovarian Cancer.
Results of Docetaxel Plus Oxaliplatin (DOCOX) +/- Cetuximab in Patients with Metastatic Gastric and/or Gastroesophageal Junction Adenocarcinoma: Results.
Phase III Trial of Pazopanib in Locally Advanced and/or Metastatic Renal Cell Carcinoma Sternberg CN et al. ASCO 2009; Abstract (Oral Presentation)
Copyright © 2011 Research To Practice. All rights reserved. Faculty National GI Tumor Board Clinical Investigators Provide Their Perspectives on Current.
NHL13: A Multicenter, Randomized Phase III Study of Rituximab as Maintenance Treatment versus Observation Alone in Patients with Aggressive B ‐ Cell Lymphoma.
1Bachelot T et al. Proc SABCS 2010;Abstract S1-6.
Randomized Phase III Trial Comparing FOLFIRINOX (F: 5FU/Leucovorin [LV], Irinotecan [I], and Oxaliplatin [O]) versus Gemcitabine (G) as First-Line Treatment.
BASED ON PROTOCOL VERSION 1 SEPTEMBER 2012 A new study evaluating an investigational drug to treat patients with HER2-positive metastatic gastroesophageal.
Ibrutinib, Single Agent or in Combination with Dexamethasone, in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (MM): Preliminary Phase.
Bevacizumab continuation versus no continuation after first-line chemo-bevacizumab therapy in patients with metastatic colorectal cancer: a randomized.
Bevacizumab plus Interferon-alpha versus Interferon-alpha Monotherapy in Patients with Metastatic Renal Cell Carcinoma: Results of Overall Survival for.
KRAS status and efficacy in the first- line treatment of patients with mCRC treated with FOLFOX with or without cetuximab: The OPUS experience Carsten.
Final Efficacy Results from OAM4558g, a Randomized Phase II Study Evaluating MetMAb or Placebo in Combination with Erlotinib in Advanced NSCLC Spigel DR.
AVADO TRIAL David Miles Mount Vernon Cancer Centre, Middlesex, United Kingdom A randomized, double-blind study of bevacizumab in combination with docetaxel.
Cmab might have therapeutic benefit in Japanese patients with KRAS p.G13D mutant colorectal cancer. Limitations of this study are its retrospective design.
Cortés J et al. ASCO 2009; Abstract (Poster Discussion)
Activation of insulin like growth factor 1 receptor (IGF-1R) signaling pathway is implicated in proliferation, survival, and angiogenesis in pancreatic.
OCEANS: A Randomized, Double- Blinded, Placebo-Controlled Phase III Trial of Chemotherapy with or without Bevacizumab (BEV) in Patients with Platinum-
Preliminary Results from a Phase II study of FOLFIRI and Bevacizumab as First Line Treatment for Metastatic Colorectal Cancer (Abstract #3579) S. Kopetz,
A Phase 2 Study of Elotuzumab in Combination with Lenalidomide and Low-Dose Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma Lonial.
Cetuximab plus FOLFIRI in the treatment of metastatic colorectal cancer: the influence of KRAS and BRAF biomarkers on outcome: updated data from the CRYSTAL.
Kang Y et al. Proc ASCO 2010;Abstract LBA4007.
Phase II trial of irinotecan/docetaxel for advanced pancreatic cancer with randomization between irinotecan/docetaxel and irinotecan/docetaxel plus C225,
Phase II trial of irinotecan/docetaxel for advanced pancreatic cancer with randomization between irinotecan/docetaxel and irinotecan/docetaxel plus C225,
The impact of smoking on cancer recurrence and survival in patients with stage III colon cancer: findings from CALGB Nadine A. Jackson, Charles S.
Gemcitabine With or Without Cisplatin in Patients with Advanced or Metastatic Biliary Tract Cancer (ABC): Results of a Multicentre, Randomized Phase III.
1 CONFIDENTIAL – DO NOT DISTRIBUTE ARIES mCRC: Effectiveness and Safety of 1st- and 2nd-line Bevacizumab Treatment in Elderly Patients Mark Kozloff, MD.
CB-1 Background of Pancreatic Cancer & NCIC CTG PA.3 Study Design Malcolm Moore, MD Professor of Medicine and Pharmacology Princess Margaret Hospital Chair,
A Phase 2 Study with a Daily Regimen of the Oral mTOR Inhibitor RAD001 (Everolimus) in Patients with Metastatic Clear Cell Renal Cell Cancer Amato RJ et.
A Multicentre Phase II Study of Cisplatin (C), Gemcitabine (G), and Bevacizumab (B) as First-Line Chemotherapy for Metastatic.
Impact of Bevacizumab (Bev) on Efficacy of Second-Line Chemotherapy (CT) for Triple- Negative Breast Cancer: Analysis of RIBBON-2 Brufsky A et al. Proc.
Cabozantinib (XL184) in metastatic castration- resistant prostate cancer (mCRPC): Results from a phase II randomized discontinuation.
P.A. Tang 1, S. J. Cohen 1, G. Bjarnason 1, C. Kollmannsberger 1, K. Virik 1, M. J. MacKenzie 1, J. Brown 1, L. Wang 1, A. Chen 2, M. J. Moore 1 1 Princess.
S1207: Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients.
A Discussion on Biologic Agents in Gastric Cancer Treatment Yoon-Koo Kang, MD Professor of Medicine Asan Medical Center University of Ulsan College of.
1 A Randomized, Multi-Center Phase III Trial of Irinotecan in Combination with Three Different Methods of Administration of Fluoropyrimidine with Celecoxib.
Moskowitz CH et al. Proc ASH 2014;Abstract 673.
Discussant: M Ducreux, MD, PhD Institut Gustave Roussy, Villejuif France TH-302 plus Gemcitabine vs. Gemcitabine in Patients with Untreated Advanced Pancreatic.
North Central Cancer Treatment Group Randomized Phase II Trial of Panitumumab, Erlotinib, and Gemcitabine (PGE) versus Erlotinib-Gemcitabine (GE) in Patients.
Erlotinib plus Gemcitabine Compared with Gemcitabine Alone in Patients with Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute.
Results of a Phase 2, Multicenter, Single-Arm Study of Eribulin Mesylate as First-Line Therapy for Locally Recurrent or Metastatic HER2-Negative Breast.
Everolimus for Advanced Pancreatic Neuroendocrine Tumors N Engl J Med 2011;364: R4. 박선희 / Prof. 동석호.
12 th Annual CTOS Meeting 2006 SINGLE AGENT DOXORUBICIN VS DOSE INTENSIVE COMBINATION THERAPY WITH EPIRUBICIN / IFOSFAMIDE IN PREVIOUSLY UNTREATED ADULT.
Phase I/II CheckMate 032: Nivolumab ± Ipilimumab in Advanced SCLC
A cura di Filippo de Marinis
CCO Independent Conference Highlights
Farletuzumab in platinum sensitive ovarian cancer with low CA125
What do we do after FOLFIRINOX? Gemcitabine-Based Therapy is Standard
KEYNOTE-012: Durable Efficacy With Pembrolizumab in PD-L1–Positive Gastric Cancer CCO Independent Conference Highlights of the 2015 ASCO Annual Meeting*
Phase 1b Study of AMG 655 in Combination With Modified FOLFOX6 (mFOLFOX6) and Bevacizumab (B) for the First-Line Treatment of Patients With Metastatic.
LV5FU2-cisplatin followed by gemcitabine or the reverse sequence in metastatic pancreatic cancer: Preliminary results of a randomized phase III trial (FFCD.
Phase 2, Randomized, Open-label Study of Cetuximab and Bevacizumab Alone or in Combination with Fixed-dose Rate (FDR) Gemcitabine as First-line Therapy.
Phase II trial of erlotinib in advanced pancreatic cancer
1University Hospital Gasthuisberg, Leuven, Belgium;
for the Cancer and Leukemia Group B
Presentation transcript:

A Placebo-Controlled, Randomized Phase 2 Study of Conatumumab (C) or AMG 479 (A) or Placebo (P) + Gemcitabine (G) in Patients (pts) With Metastatic Pancreatic Cancer (mPC) HL Kindler,1 D Richards,2 J Stephenson,3 L Garbo,4 C Rocha Lima,5 H Safran,6 J Wiezorek,7 E Feigal,7 SL Bray,8 CS Fuchs9 1University of Chicago Medical Center, Chicago IL 2US Oncology Research, Tyler, TX 3Greenville Hospital System, Greenville, SC 4New York Oncology Hematology, P.C. Albany, Albany, NY 5University of Miami, Sylvester Comprehensive Cancer Center, Miami, FL 6Rhode Island Hospital, Providence, RI 7Amgen Inc., Thousand Oaks, CA 8Amgen Ltd, Cambridge, UK 9Dana-Farber Cancer Institute, Boston, MA Abstract #4035

BACKGROUND The DR5/TRAIL Pathway in Pancreatic Cancer Pancreatic tumors express higher levels of death receptor 5 (DR5) than normal pancreas1 Mutations in KRAS are found in > 90% of pancreatic cancer (PC)2 Transformation by RAS sensitizes cells to TRAIL-induced apoptosis3,4 Conatumumab (AMG 655) is an investigational, fully human, monoclonal antibody agonist of DR5 Binds DR5, activates caspases, and induces apoptosis5 In mouse models of PC, conatumumab demonstrated single-agent activity, which was enhanced in combination with gemcitabine5 In a phase 1b study in metastatic PC patients, conatumumab appeared safe in combination with gemcitabine6 Disease control rate (partial response [PR] + stable disease [SD]) = 69%; 6-month overall survival (OS) = 76%

BACKGROUND The DR5/TRAIL Pathway in Pancreatic Cancer

BACKGROUND The Type 1 Insulin-Like Growth Factor Receptor (IGF-1R) Pathway and Pancreatic Cancer IGF1-R, IGF-1, and IGF-2 are over-expressed in PC cells and tumors Risk of PC increases in patients with increased pathway activity (insulin sensitivity, Akt2 amplification, and low serum IGFBP-1) Pharmacological and genetic blockade of IGF-1R activity inhibits the growth of multiple PC xenograft models (alone and in combination with gemcitabine) Tumors driven by KRAS remain sensitive to IGF-1R inhibition7-9 AMG 479 is an investigational, fully human, monoclonal antibody antagonist of IGF-1R Blocks binding of IGF-1 and IGF-2 to IGF-1R8 In mouse models of PC, AMG 479 demonstrated single-agent activity; activity was enhanced in combination with gemcitabine8 In a phase 1b study in patients with advanced solid tumors, AMG 479 appeared safe in combination with gemcitabine10

BACKGROUND The Type 1 Insulin-Like Growth Factor Receptor (IGF-1R) Pathway and Pancreatic Cancer

STUDY RATIONALE Current therapies for PC are inadequate: novel approaches are required Preclinical and phase I data support the evaluation of conatumumab and AMG 479 in PC patients Randomized phase II studies may be superior to single-arm trials in evaluating novel agents in PC Therefore, a 3-arm, placebo-controlled, randomized phase 2 study was conducted to evaluate conatumumab + gemcitabine and AMG 479 + gemcitabine versus placebo + gemcitabine in metastatic PC patients

PRIMARY ENDPOINT 6-month OS rate

METHODS Study Schema aThe AMG 479 + gemcitabine arm was open label due to anticipated thrombocytopenia and hyperglycemia.

METHODS Secondary Endpoints Response rate (by RECIST) Investigator defined, no central review Progression-free survival (PFS, investigator defined) OS Incidence of adverse events (AE) and laboratory abnormalities Incidence of anti-conatumumab or anti-AMG 479 antibodies Pharmacokinetics of conatumumab and AMG 479 Dose intensity of gemcitabine when combined with conatumumab, AMG 479, or placebo

METHODS Key Inclusion Criteria Histologically or cytologically documented metastatic adenocarcinoma of the pancreas ≥ 18 years of age ECOG PS 0 or 1 Adequate hematologic, hepatic, renal, and coagulation function Amylase and lipase ≤ 2.0 x ULN Adequately controlled type 1 or 2 diabetes (amended during study to FBS <160 mg/dL only) Fasting blood sugar ≤ 160 mg/dL HbA1c < 8% Written informed consent

METHODS Key Exclusion Criteria Uncontrolled cardiac disease Prior chemotherapy or radiation in the adjuvant or metastatic setting

METHODS Statistics The study was designed as an estimation study Planned sample size of 120 (40/arm) As designed (estimation, not hypothesis-testing), the trial has 80% power to detect a difference between a 6-month OS rate of: 45% for placebo 69% for conatumumab or AMG 479 (target improvement, 10%)

RESULTS Baseline Demographics

RESULTS Baseline Lesion Sites

RESULTS Efficacy aPrimary endpoint. HR, hazard ratio; CI, confidence interval. The PFS and OS results were robust after adjusting for baseline covariates (age, gender, ECOG PS status, liver metastases, and tumor sum of longest diameter)

RESULTS Progression-Free Survival Full analysis set. aStratified hazard ratio (estimates relative to placebo + gemcitabine arm). bStratified log-rank test. HR, hazard ratio; KM, Kaplan-Meier; CI, confidence interval.

RESULTS Overall Survival Full analysis set. aStratified hazard ratio (estimates relative to placebo + gemcitabine arm). bStratified log-rank test.

RESULTS Best Overall Tumor Response CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease.

RESULTS Grade 3-5 Adverse Eventsa aIn ≥ 5% of patients. bOne GI perforation, 1 GI hemorrhage, 1 hepatic failure in a patient with liver metastases, 4 PD. cOne acute renal failure, 1 hemorrhage, 2 PD. dOne GI hemorrhage.

RESULTS Drug Exposure aRatio of cumulative dose of drug : protocol-specified cumulative dose over the specified period. IP, investigational product.

CONCLUSIONS This randomized phase 2 study shows evidence of activity for AMG 479 with trends across several efficacy parameters in metastatic PC Improved 6-month OS rate (primary endpoint) (57% vs 50%) Improved 12-month OS (39% vs 23%) Longer PFS (5.1 vs 2.1 months, HR 0.65) Longer OS (8.7 vs 5.9 months, HR 0.67) Higher rates of SD + PR (51% vs 41%)

CONCLUSIONS (continued) The study also shows evidence of activity for conatumumab Improved 6-month OS rate (primary endpoint) (59% vs. 50%) Longer PFS (4.0 vs 2.1 months, HR 0.65) Higher rates of SD + PR (61% vs 41%) Both drug combinations were well-tolerated These data suggest that further study of AMG 479 + gemcitabine is warranted in advanced PC

REFERENCES 1. Data on file. Amgen Inc. 2. Koorstra JB, et al. Pancreatology. 2008;8:110-125. 3. Nesterov AM, et al. Cancer Res. 2004;64:3922-3927. 4. Drosopoulos KG, et al. J Biol Chem. 2005;280:22856-22867. 5. Kaplan-Lefko PJ, et al. Cancer Biol Ther. 2010;9:618-631. 6. Kindler HL, et al. J Clin Oncol. 2009;27:abstr 4501. 7. Beltran PJ, et al. Mol Cancer Ther. 2009;8:1095-1105. 8. Sell C, et al. Mol Cell Biol. 1994;14:3604-3612. 9. Yeh AH, et al. Oncogene. 2006;25:6574-6581. 10. Sarantopoulos J, et al. J Clin Oncol. 2008;26:abstr 3583.

ACKNOWLEDGMENTS This study was sponsored by Amgen Inc. (ClinicalTrials.gov: NCT00630552)